This brand name is authorized in Nigeria.
The drug JAWALK contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
EE90ONI6FF - POTASSIUM CITRATE
|
|
Citrate and citric acid solutions are systematic and urinary alkalinizers thereby providing symptomatic relief of dysuria. |
|
2
|
UNII
2968PHW8QP - CITRIC ACID MONOHYDRATE
|
|
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| A11-0138 | Solution | JAWALK ORAL SOLUTION SOL 1100 mg5 mL; 334 mg/5 mL 100ML,200ML | JAWALK ORAL SOLUTION POTASSIUM CITRATE MONOHYDRATE 1100MG, CITRIC ACID MONOHYDRATE 334MG Potassium Citrate Monohydrate 1100mg Citric Acid Monohydrate 334mg Sorbitol 70% solution Methyl Paraben Propylene Glycol Sunset yellow color Raspberry flavor Sodium saccharin Sodium benzoate A11-0138 Drugs GENITO URINARY SYSTEM AND SEX HORMONES Nigerian Products 100ML,200ML OTC 10/11/2021 JAWA INTERNATIONAL LIMITED, Plot 6, Abimbola Way, Isolo Industrial Estate | 30/11/2023 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A12BA02 | Potassium citrate | A Alimentary tract and metabolism → A12 Mineral supplements → A12B Potassium → A12BA Potassium |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | A11-0138 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.